Thrombin activatable fibrinolysis inhibitor and thrombin-antithrombin-III-complex levels in patients with gastric cancer

[1]  A. Kosar,et al.  Thrombin-Activatable Fibrinolysis Inhibitor in Breast Cancer Patients , 2011, Medical Principles and Practice.

[2]  Young Hak Kim,et al.  Clinical significance of the ratio between the alpha 2 plasmin inhibitor–plasmin complex and the thrombin–antithrombin complex in advanced non-small cell lung cancer , 2011, Medical oncology.

[3]  A. Jemal,et al.  Global Cancer Statistics , 2011 .

[4]  K. Gomes,et al.  D-dimer as a possible prognostic marker of operable hormone receptor-negative breast cancer. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[5]  L. Glavaš-Obrovac,et al.  An overview of coagulation disorders in cancer patients. , 2010, Surgical oncology.

[6]  S. Kiňová,et al.  General changes in hemostasis in gastric cancer. , 2009, Bratislavske lekarske listy.

[7]  D. Erdem,et al.  Relation between hemostatic parameters and prognostic/predictive factors in breast cancer. , 2008, European journal of internal medicine.

[8]  Hyo-jin Kim,et al.  Plasma levels of prothrombin fragment F1+2, D-dimer and prothrombin time correlate with clinical stage and lymph node metastasis in operable gastric cancer patients. , 2008, Japanese journal of clinical oncology.

[9]  H. Imamura,et al.  Poor prognosis associated with thrombocytosis in patients with gastric cancer , 2002, Annals of Surgical Oncology.

[10]  B. Bouma,et al.  Thrombin activatable fibrinolysis inhibitor (TAFI)--how does thrombin regulate fibrinolysis? , 2006, Annals of medicine.

[11]  畑地 治.  Increased circulating levels of thrombin-activatable fibrinolysis inhibitor in lung cancer patients , 2005 .

[12]  M. De Cicco.  The prothrombotic state in cancer: pathogenic mechanisms. , 2004, Critical reviews in oncology/hematology.

[13]  O. Franco,et al.  Thrombin-activatable fibrinolysis inhibitor and protein C inhibitor in interstitial lung disease. , 2003, American journal of respiratory and critical care medicine.

[14]  J. Meijers,et al.  Thrombin-activatable fibrinolysis inhibitor (TAFI, plasma procarboxypeptidase B, procarboxypeptidase R, procarboxypeptidase U). , 2001, Thrombosis research.

[15]  L. Zacharski.  Anticoagulants in cancer treatment: malignancy as a solid phase coagulopathy. , 2002, Cancer letters.

[16]  G. Lip,et al.  Cancer and the prothrombotic state. , 2002, The Lancet. Oncology.

[17]  J. Meijers,et al.  Thrombin‐activatable fibrinolysis inhibitor (TAFI, plasma procarboxypeptidase B, procarboxypeptidase R, procarboxypeptidase U) , 2003, Journal of thrombosis and haemostasis : JTH.

[18]  R. Torella,et al.  Alteration of haemostasis in non-metastatic gastric cancer. , 2001, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[19]  D. Ferrigno,et al.  Prognostic significance of blood coagulation tests in lung cancer. , 2001, The European respiratory journal.

[20]  L. Bajzar.  Thrombin Activatable Fibrinolysis Inhibitor and an Antifibrinolytic Pathway , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[21]  S. Kitano,et al.  Pathology and prognosis of gastric carcinoma , 2000, Cancer.

[22]  J. Meijers,et al.  Reduced activity of TAFI (thrombin‐activatable fibrinolysis inhibitor) in acute promyelocytic leukaemia , 2000, British journal of haematology.

[23]  G. Hawson,et al.  Alterations to the fibrinolytic enzyme system in patients with non-small cell lung carcinoma. , 1999, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[24]  J. Siewert,et al.  Relevant prognostic factors in gastric cancer: ten-year results of the German Gastric Cancer Study. , 1998, Annals of surgery.

[25]  Ş. Kirazlı,et al.  Haemostatic Changes; Plasma Levels of Alpha2-Antiplasmin-Plasmin Complex and Thrombin-Antithrombin III Complex in Female Breast Cancer , 1998 .

[26]  J. Biggerstaff,et al.  Hemostasis and Malignancy , 1998, Seminars in thrombosis and hemostasis.

[27]  R. Seitz,et al.  Prognostic impact of an activation of coagulation in lung cancer. , 1997, Annals of oncology : official journal of the European Society for Medical Oncology.

[28]  M. Nesheim,et al.  The profibrinolytic effect of activated protein C in clots formed from plasma is TAFI-dependent. , 1996, Blood.

[29]  N. Milman,et al.  Prognostic significance of thrombocytosis in patients with primary lung cancer. , 1996, The European respiratory journal.

[30]  H. Gralnick,et al.  Coagulation disorders in cancer. , 1996, Hematology/oncology clinics of North America.

[31]  A. Lopes,et al.  Thrombocytosis as a prognostic factor in women with cervical cancer , 1994, Cancer.

[32]  T. Yao,et al.  Pathology and prognosis of gastric carcinoma. Findings in 10,000 patients who underwent primary gastrectomy , 1992, Cancer.

[33]  Thomas E. Moritz,et al.  Abnormalities of blood coagulation tests in patients with cancer. , 1987, American journal of clinical pathology.

[34]  J. Efskind,et al.  The pathology and prognosis of gastric carcinoma. , 1960, Acta chirurgica Scandinavica. Supplementum.